A 20-year veteran of medical devices, Hanson operated most recently as group president of Fridley, Minn.-based Medtronic’s approximately $9 billion minimally invasive therapies group, Zimmer Biomet said.
Prior to his time with Medtronic, Hanson held positions as group president of Covidien’s medical device business, and group president of surgical solutions.
“On behalf of the board, I am thrilled to welcome Bryan to the Zimmer Biomet team. The board of directors, with the assistance of a leading executive search firm, carefully identified, evaluated and interviewed a number of highly-qualified candidates and concluded that Bryan is the best fit to lead the company. Bryan is a proven executive with a track record of successfully leading, growing and transforming global medical device businesses to achieve higher levels of innovation, commercial success and profitability. This leadership announcement comes at an important time in Zimmer Biomet’s history, and we look forward to working closely with Bryan to further leverage our leading portfolio of technologies, solutions and personalized services to enhance stockholder value. On behalf of everyone at Zimmer Biomet, I want to thank Dan for serving as the company’s Interim CEO for the past five months. We are grateful that Dan assumed this role at such an important time, and we look forward to continuing to benefit from his expertise through his ongoing service as CFO,” Zimmer Biomet chair Larry Glasscock said in a prepared statement.
“I am honored and excited to join the talented team at Zimmer Biomet. I have long admired Zimmer Biomet, including its strong brand, commercial excellence and market-leading salesforce, healthy portfolio of marquee products and strong innovation pipeline. I share the company’s purpose of improving the quality of life for patients and I look forward to deeply familiarizing myself with Zimmer Biomet’s global operations to ensure we have the right foundation in place to support our customers and the patients they serve around the world, while driving sustained shareholder value,” Hanson said in a prepared release.
“It has been a privilege to lead the Zimmer Biomet organization as interim CEO. I join the rest of the management team in welcoming Bryan, and I am confident the company will thrive under his leadership,” Florin said in a press release.
Medtronic (NYSE:MDT) said today it is promoting former Asia Pacific region senior VP Bob White to exec VP and prez of its minimally invasive therapies group to replace a departing Bryan Hanson, who left the company to become prez & CEO of Zimmer Biomet.
White originally joined Medtronic when it closed its Covidien acquisition in 2015 as the prez for the APAC region, based in Singapore.
In addition to White’s promotion, the Fridley, Minn.-based medtech giant said it is promoting senior VP and greater China region prez Chris Lee to White’s vacated position as APAC region prez. Lee will also remain as interim prez of the greater China region until a successor is named “in the coming weeks,” the company said.
Prior to joining Medtronic, Lee served as greater China region prez for Bayer HealthCare, the company said.
“We are pleased to name Bob White and Chris Lee to these new leadership assignments. Their extensive knowledge and expertise of the Medtronic businesses and regions involved – as well as their demonstrated track records of success – will ensure continuity to our overall business strategies and objectives. Bob is uniquely qualified to take on the MITG role given his prior leadership experience in the former Covidien company and his most recent role as President of our APAC region, where he was responsible for advancing MITG and our three other groups in the region. Chris has strong experience across Asia Pacific, having previously led the operations of several leading pharmaceutical companies in the region. Both Bob and Chris have strong records of delivering results, and I look forward to working with them in their new roles. We thank Bryan for his contributions to Medtronic through the Covidien acquisition, its integration into Medtronic and to its current, solid performance as the minimally invasive therapies group. We wish him and his family well with his new endeavor,” CEO & chair Omar Ishrak said in a prepared statement.
InVivo Therapeutics (NSDQ:NVIV) said today its current CEO and board chair Mark Perrin has resigned from the corner office, with chief medical officer Dr. Richard Toselli stepping in as acting chief executive and Ann Merrifield taking over as board chair.
Dr. Toselli will continue in their capacity as chief medical officer, and Perrin will remain with the company as a consultant for six months, the Cambridge, Mass.-based company said.
“I am confident in Dr. Toselli’s ability to lead InVivo forward. His background in surgical device innovation and neurological surgery will be critical as the company progresses its promising technology addressing the substantial needs in treating patients with spinal cord injury,” co-founder & scientific advisory board member Robert Langer said in prepared remarks.
“As announced earlier this quarter, the company continues to engage with the FDA to understand how we can reset the Neuro-Spinal Scaffold clinical program, which is currently on hold. We look forward to continued discussions with the FDA with the goal of providing additional clarity on the Neuro-Spinal Scaffold program in the near term,” Dr. Toselli said in a press release.
“We are pleased to have Dr. Toselli accept the role as acting chief executive officer. He brings a successful track record in clinical and regulatory affairs advancing transformational technologies, and following our recent discussions with the FDA, we believe Dr. Toselli’s experience and capabilities are well-suited to the important work ahead,” Merrifield said in a prepared statement.
“It was extremely rewarding to initiate the first-in-man clinical trial of the Neuro-Spinal Scaffold and to learn from the results thus far from the Inspire trial. I wish the InVivo Board and management team the best in their pursuit of the company’s mission to redefine the lives of spinal cord-injured patients,” Perrin said in a prepared release.
Milestone Scientific (NYSE:MLSS) said yesterday that its former CEO Leonard Osser has been appointed as interim CEO, effective immediately, replacing board chair Leslie Bernhard who will remain at the head of the company’s board of directors.
“As founder of the company, Leonard Osser has been instrumental in both the growth and strategic vision for the Company. While we are continuing our search for a new CEO, this process has been slower than expected because the Company has been focused on several ongoing strategic initiatives that Leonard is spearheading. For this reason, he has graciously agreed to resume the role as CEO pending completion of these major projects and selection of a new long-term CEO. We greatly appreciate his support and believe his continued involvement both at the executive and board level will be invaluable to our long-term success. I am more excited than ever about the long-term outlook for Milestone given the recent FDA approval of our epidural instrument on the heels of our successful clinical trial, the planned launch of our cosmetic instrument and the success of our distribution partnership with Henry Schein for the dental instrument. We have garnered significant interest in each of these instruments, as well as others, and we look forward to providing further updates in the months ahead,” Bernhard said in a press release.
The move is retroactively effective to December 15, the Clearwater, Fla.-based company said. As part of the promotion, Goodwin will also join the company’s board of directors.
“After thorough consideration, The board of directors has voted unanimously to appoint Charlie to the role of chief executive officer. The appointment of Mr. Goodwin represents an important strategic decision for Bovie Medical as we pursue strong growth performance and improving profitability. Charlie is the ideal executive to lead the company on its next stage of growth. Over the course of his nearly 25-year career in the medical device industry, Charlie has a demonstrated track record of delivering strong revenue growth and operational excellence. As Vice President of Olympus Corporation’s global surgical energy group for five years, Charlie was directly responsible for the group’s global commercial strategy, managing a team of over 500 employees with full profit and loss responsibility. Prior to joining Olympus, Charlie was the President of Worldwide Sales at Gyrus ACMI, where he led the business to record growth in sales and profit, and served as a key member of the executive team that negotiated the acquisition of Gyrus ACMI by Olympus for $2.2 billion. Before his promotion to President of Worldwide Sales, Charlie was instrumental in developing Gyrus’s global distribution network as President, Surgical Division, where he achieved average annual sales growth of 35% for three consecutive years. The Board is confident that he will drive growth and enhance the Company’s operational performance, which together we believe will increase shareholder value going forward,” board chair Andrew Makrides said in a prepared statement.
“I am excited to lead Bovie Medical as the Company commercializes its transformational J-Plasma technology and continues to grow sales. J-Plasma represents an exciting step forward from the surgical energy technologies that have been traditionally applied in these markets, with its potential in several surgical specialties to improve surgical precision and enhance procedure safety by minimizing collateral tissue damage. I am looking forward to working together with our employees and the Board to continue to drive the commercial adoption of this unique, cutting edge energy technology, for the benefit of our customers and shareholders,” Goodwin said in a press release.